PATENT CLAIM ANALYSIS

Application Number: 15952234
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "264110"]

Abstract:
Provided are a hydroxyethyl sulfonate of a cyclin-dependent protein kinase inhibitor, a crystalline form thereof and a preparation method therefor. Specifically, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydroxyethyl sulfonate (compound of formula (I)), a crystal form I thereof and a preparation method therefor are provided. Crystal form I of the compound of formula (I) has good chemical and crystalline stability, low toxicity, and low residual crystallization solvent. The compound of formula (I) and crystal form I thereof can be used in improved clinical therapy.

Claim (Index 16):
A method of treating a disease related to cyclin dependent kinase (CDK4&6) in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition according to  claim 13 , wherein the disease is a cancer.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 91.0
- Lexical Diversity: 1.98276
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15546405', '16310369', '15559516', '15516529', '11861958']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7833568377281247
- 35 USC 102 Novelty (BERT): 0.5553271127324221
- Combined Prediction Score: 0.7605538652285545
- Mean Citation Score: 303.985086
- Max Citation Score: 448.03943
- Similarity Product: 314.1834917489177

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test